Atezolizumab for Non-Small Cell Lung Cancer

This trial tests whether atezolizumab, alone or with an enzyme called recombinant human hyaluronidase, can prevent non-small cell lung cancer (NSCLC) from returning after surgery. Atezolizumab is an immunotherapy treatment that helps the immune system attack cancer cells. The trial compares these treatments to the usual practice of observation after surgery. It suits those who have had a complete surgical removal of stage I NSCLC and meet specific medical criteria, including no history of certain genetic mutations or uncontrolled health conditions. As a Phase 3 trial, this study represents the final step before FDA approval, offering patients a chance to contribute to potentially groundbreaking cancer treatment advancements.

The trial protocol does not specify if you need to stop taking your current medications. However, you should not have uncontrolled illnesses or be on continuous systemic corticosteroids or other immunosuppressive medications within 14 days before joining the trial. It's best to discuss your specific medications with the trial team.

Research has shown that atezolizumab is generally well-tolerated. In studies involving patients with non-small cell lung cancer (NSCLC), atezolizumab proved to be safe. Some patients experienced side effects, similar to those seen with other cancer treatments, and serious side effects occurred in about 27% of patients.

When combined with recombinant human hyaluronidase, known as Tecentriq Hybreza, the results remain positive. Studies indicate that this combination is safe and works as well as atezolizumab alone. This combination helps the medicine enter the body more efficiently.

Researchers are excited about atezolizumab for non-small cell lung cancer because it works by harnessing the body's own immune system to fight cancer cells. Unlike traditional chemotherapy that directly attacks cancer cells but can also harm healthy cells, atezolizumab targets the PD-L1 protein, helping the immune system recognize and destroy cancer cells more effectively. Moreover, the combination with recombinant human hyaluronidase offers a potential new delivery method, making the treatment more convenient by allowing a quicker administration under the skin instead of the longer intravenous infusion. These features have the potential to improve both the effectiveness and the experience of treatment for patients.

This trial will compare observation with treatment using atezolizumab for non-small cell lung cancer (NSCLC). Studies have shown that atezolizumab can help people with advanced NSCLC live longer. Specifically, one study found that patients receiving atezolizumab lived an average of 13.8 months, compared to 9.6 months for those on another chemotherapy drug. For early-stage NSCLC, atezolizumab has significantly extended the time patients live without cancer recurrence after surgery and chemotherapy, particularly in patients with certain tumor markers (PD-L1+). Research also indicates that when combined with recombinant human hyaluronidase, it performs as well and is as safe as the intravenous form of atezolizumab. Overall, atezolizumab shows promise in preventing cancer recurrence in NSCLC patients.¹⁶⁷⁸⁹